OBJECTIVE: Activation of the renal renin-angiotensin system in patients with diabetes mellitus appears to contribute to the risk of nephropathy. Recently, it has been recognized than an elevation of prorenin in plasma also provides a strong indication of risk of nephropathy. This study was designed to examine renin-angiotensin system control mechanisms in the patient with diabetes mellitus. METHODS: We enrolled 43 individuals with type 2 diabetes mellitus. All individuals were on a high-salt diet to minimize the contribution of the systemic renin-angiotensin system. After an acute exposure to captopril (25 mg), they were randomized to treatment with either irbesartan (300 mg) or aliskiren (300 mg) for 2 weeks. RESULTS: All agents acutely lowered blood pressure and plasma aldosterone, and increased renal plasma flow and glomerular filtration rate. Yet, only captopril and aliskiren acutely increased plasma renin and decreased plasma angiotensin II, whereas irbesartan acutely affected neither renin nor angiotensin II. Plasma renin and angiotensin II subsequently did increase upon chronic irbesartan treatment. When given on day 14, irbesartan and aliskiren again induced the above hemodynamic, renal and adrenal effects, yet without significantly changing plasma renin. Irbesartan at that time did not affect plasma angiotensin II, whereas aliskiren lowered it to almost zero. CONCLUSION: The relative resistance of the renal renin response to acute (irbesartan) and chronic (irbesartan and aliskiren) renin-angiotensin system blockade supports the concept of an activated renal renin-angiotensin system in diabetes, particularly at the level of the juxtaglomerular cell, and implies that diabetic patients might require higher doses of renin-angiotensin system blockers to fully suppress the renal renin-angiotensin system.
RCT Entities:
OBJECTIVE: Activation of the renal renin-angiotensin system in patients with diabetes mellitus appears to contribute to the risk of nephropathy. Recently, it has been recognized than an elevation of prorenin in plasma also provides a strong indication of risk of nephropathy. This study was designed to examine renin-angiotensin system control mechanisms in the patient with diabetes mellitus. METHODS: We enrolled 43 individuals with type 2 diabetes mellitus. All individuals were on a high-salt diet to minimize the contribution of the systemic renin-angiotensin system. After an acute exposure to captopril (25 mg), they were randomized to treatment with either irbesartan (300 mg) or aliskiren (300 mg) for 2 weeks. RESULTS: All agents acutely lowered blood pressure and plasma aldosterone, and increased renal plasma flow and glomerular filtration rate. Yet, only captopril and aliskiren acutely increased plasma renin and decreased plasma angiotensin II, whereas irbesartan acutely affected neither renin nor angiotensin II. Plasma renin and angiotensin II subsequently did increase upon chronic irbesartan treatment. When given on day 14, irbesartan and aliskiren again induced the above hemodynamic, renal and adrenal effects, yet without significantly changing plasma renin. Irbesartan at that time did not affect plasma angiotensin II, whereas aliskiren lowered it to almost zero. CONCLUSION: The relative resistance of the renal renin response to acute (irbesartan) and chronic (irbesartan and aliskiren) renin-angiotensin system blockade supports the concept of an activated renal renin-angiotensin system in diabetes, particularly at the level of the juxtaglomerular cell, and implies that diabeticpatients might require higher doses of renin-angiotensin system blockers to fully suppress the renal renin-angiotensin system.
Authors: Deborah A Price; Naomi D L Fisher; M Cecilia Lansang; Radomir Stevanovic; Gordon H Williams; Norman K Hollenberg Journal: Hypertension Date: 2002-08 Impact factor: 10.190
Authors: Norman K Hollenberg; Deborah A Price; Naomi D L Fisher; M Cecilia Lansang; Bruce Perkins; Michael S Gordon; Gordon H Williams; Lori M B Laffel Journal: Kidney Int Date: 2003-01 Impact factor: 10.612
Authors: D A Price; L E Porter; M Gordon; N D Fisher; J M De'Oliveira; L M Laffel; D R Passan; G H Williams; N K Hollenberg Journal: J Am Soc Nephrol Date: 1999-11 Impact factor: 10.121
Authors: M P Schuijt; M Basdew; R van Veghel; R de Vries; P R Saxena; R G Schoemaker; A H Danser Journal: Am J Physiol Heart Circ Physiol Date: 2001-12 Impact factor: 4.733
Authors: Lodi C W Roksnoer; Bart F J Heijnen; Daisuke Nakano; Janos Peti-Peterdi; Stephen B Walsh; Ingrid M Garrelds; Jeanette M G van Gool; Robert Zietse; Harry A J Struijker-Boudier; Ewout J Hoorn; A H Jan Danser Journal: Hypertension Date: 2016-02-29 Impact factor: 10.190
Authors: Lodi C W Roksnoer; Koen Verdonk; Anton H van den Meiracker; Ewout J Hoorn; Robert Zietse; A H Jan Danser Journal: Curr Hypertens Rep Date: 2013-04 Impact factor: 5.369
Authors: Hui Lin; Frank Geurts; Luise Hassler; Daniel Batlle; Katrina M Mirabito Colafella; Kate M Denton; Jia L Zhuo; Xiao C Li; Nirupama Ramkumar; Masahiro Koizumi; Taiji Matsusaka; Akira Nishiyama; Martin J Hoogduijn; Ewout J Hoorn; A H Jan Danser Journal: Pharmacol Rev Date: 2022-07 Impact factor: 18.923
Authors: David Z I Cherney; Heather N Reich; James W Scholey; Denis Daneman; Farid H Mahmud; Ronnie L H Har; Etienne B Sochett Journal: Diabetologia Date: 2013-07-28 Impact factor: 10.122
Authors: J M van Rooyen; M Poglitsch; H W Huisman; Cmc Mels; R Kruger; L Malan; S Botha; L Lammertyn; L Gafane; A E Schutte Journal: J Renin Angiotensin Aldosterone Syst Date: 2016-10-12 Impact factor: 1.636
Authors: Bibi S van Thiel; Janette van der Linden; Yanto Ridwan; Ingrid M Garrelds; Marcel Vermeij; Marian C Clahsen-van Groningen; Fatimunnisa Qadri; Natalia Alenina; Michael Bader; Anton J M Roks; A H Jan Danser; Jeroen Essers; Ingrid van der Pluijm Journal: Int J Mol Sci Date: 2021-11-18 Impact factor: 5.923